| 名稱 | ADCP Bioassay Effector Cell FcγRIIa （H variant）-NF |
| 型號 | CBP74106 |
| 報價 |  |
| 特點 | ADCP Bioassay Effector Cell FcγRIIa （H variant）-NFAT/Jurkat，母細胞：Jurkat，凍存條件：90% FBS+10% DMSO |
產品搜索
相關文章
聯系我們
產品展示 / PRODUCTS
- 詳細內容
| I. Background | |
ADCP（Antibody dependent cellular phagocytosis）是抗體依賴性細胞介導的吞噬作用。 是一種免疫消除機制，其憑借單克隆抗體（mAb）靶向腫瘤細胞，以促進吞噬免疫細胞將 腫瘤細胞從體內清除。ADCP 由單核細胞、巨噬細胞、嗜中性粒細胞和樹突細胞通過表達 FcγRIIa（CD32a）、FcγRI（CD64）和 FcγRIIIa（CD16a）來介導來吞噬疾病細胞，研究表 明 FcγRIIa 是參與該過程的 FcγR 受體。 | |
| II. Description | |
ADCP Bioassay Effector Cell FcγRIIa(H variant) -NFAT Jurkat 報告基因藥靶模型很好的 模擬了體內 ADCP 的信號轉導過程，原理見下圖所示。
Figure 1. ADCP Bioassay Effector Cell FcγRIIa(H variant) -NFAT Jurkat 細胞模型原理圖 | |
| III. Introduction | |
| Host Cell: | Jurkat |
| Expressed gene: | FcγRIIa (H variant)-NFAT |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+1 μg/ml Puromycin+400 μg/ml Hygromycin B |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| IV. Description of Host Cell Line | |
| Organism: | Human |
| Tissue: | Peripheral blood |
| Disease: | Childhood T acute lymphoblastic leukemia |
| Morphology: | Lymphoblast |
| Growth Properties: | Suspension |
| Ⅴ. Representative Data | |
Figure 2. Dose Response of Rituximab in ADCP Bioassay Effector Cell FcγRlla (H variant) -NFAT Jurkat (C2) with Raji. | |
